Decreased fibrinolytic capacity has been sug-
intances, the level of PAM-mRNA was correlated with the degree of atherosclerosis. Analysis of adjacent tissue sections from the same patients by in situ hybridization demonstrated an abundance of PAT-i mRNA-positive cells within the thickened intima of atherosclerotic arteries, mainly around the base of the plaque. PAM-mRNA could also be detected in cells scattered within the necrotic material and in endothellal cells of adventitial vessels. In contrast to these results, PAM-mRNA was visualized primarily within luminal endothelial cells of normal-appearing aortic tissue. Our data provide initial evidence for the increased expression of PAM-mRNA in severely atherosclerotic human arteries and suggest a role for PAM-in the progression of human atherosclerotic disease.
The fibrinolytic potential of blood is regulated by the action of specific plasminogen activator inhibitors (PAIs). Endothelial or type 1 PAI (PAI-1) is a fast-acting inhibitor of both urokinase-and tissue-type plasminogen activators (1) and appears to have a major clinical relevance. Deficiencies in its activity result in an increased likelihood of hemorrhagic events (2) , whereas increased levels are frequently observed in association with thrombotic phenomena. For example, elevations in plasma PAT-i activity have been demonstrated in patients with deep venous thrombosis (3, 4) and disseminated intravascular coagulation (5) (6) (7) . In addition, increased PAT-i levels have been observed in patients with coronary artery disease (8, 9) and angina pectoris (10) and in young (11) and old (12) survivors of myocardial infarction, suggesting that PAT-i may represent a risk factor for acute coronary thrombosis (reviewed in ref. 13) .
Positive correlations have also been established between plasma PAT-i levels and known risk factors for the development of atherosclerosis. These include obesity (14) , noninsulin-dependent diabetes (15) , hyperinsulinemia (16) , and hypertriglyceridemia (11, 16) . Recently, PAI-1 was found to be predictive of coronary atherosclerosis in patients with glucose intolerance and presenting with previous myocardial infarction (17 (20 ,u) containing 0.6 x 106 cpm of radiolabeled probe (see below) and yeast tRNA at 2.5 mg/ml was then added, and the slides were hybridized for 16 hr at 55°C. After hybridization, the sections were washed twice with 2x SSC (10 min per wash at 23°C), treated with RNase A (10 ,ug/ml in 500 mM NaCl/10 mM Tris-HCl, pH 7.6, for 30 min at 23°C), and washed twice with 2x SSC (10 min per wash at 23°C) and once with 0.1 x SSC at 60°C for 2 hr. The sections were then washed twice in 0.5x SSC without 2-mercaptoethanol (10 min per wash at 23°C) and dehydrated in a graded alcohol series containing 0.3 M CH3COONH4. For detection of the hybridization signal, the sections were coated with NTB2 emulsion (Kodak) diluted 1:2 in distilled water and exposed in the dark at 4°C for 4 weeks. The slides were then developed for 2 min in D19 developer (Kodak), fixed, washed three times in distilled water (5 min per wash), and counterstained with hematoxylin and eosin by standard procedures.
Probes. For Northern analysis, a DNA fragment corresponding to bases 1-1249 of the human PAI-i cDNA (21) or a plasmid containing a cDNA insert for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH; American Type Culture Collection) were radiolabeled to a specific activity of >5 x 108 cpm/,ug by the random primer technique (22) (Fig. 1) . The PAI-1 and GAPDH mRNA autoradiographic signals were quantitated by scanning densitometry, and the densitometric value for PAl-1 mRNA was normalized to that of GAPDH as detailed in Methods. The normalized data for the 16 samples analyzed is shown in Fig. 2 . Statistical analysis revealed that the level of PAI-1 mRNA was significantly increased in vessels with severe atherosclerotic involvement (mean densitometric value, 1.7 + 0.28 SEM) relative to normal or mildly involved vessels (0.63 + 0.09 SEM; P < 0.05).
In Situ Hybridization. To localize PAI-1 mRNA within the arterial specimens, in situ hybridization was performed on parallel tissue sections. In the normal or mildly involved arteries, a strong positive hybridization signal was observed in the majority of luminal endothelial cells, while a somewhat weaker signal was observed in scattered stromal cells of the intima (Fig. 3A Upper) . No positive signal could be visualized in the media (Fig. 3A Lower) Quantitative analysis of PAI-1 mRNA expression in arterial tissues. PAI-1 and GAPDH mRNA levels in normalappearing or severely atherosclerotic arterial specimens were determined by Northern blot analysis of total RNA as depicted in Fig. 1 observed within the thickened intima and in the endothelium of adventitial arterioles but not in the luminal endothelium (Fig. 3B) . In general, the luminal endothelium of the severely diseased vessels (Fig. 3B Top Left) (Fig. 3B Middle Right) . In the adventitia of severely atherosclerotic aortas, extramural arterioles exhibited a positive hybridization signal in the arteriolar endothelium (Fig. 3B Bottom) . In addition, scattered extravascular foci containing PAI-1 mRNA could be seen in the fibrous and adipose tissue of the adventitia. Control hybridizations using a sense PAI-1 riboprobe were uniformly negative (data not shown).
DISCUSSION
Intravascular or mural thrombosis is a frequent histologic feature of atherosclerotic lesions and appears to play a role in the intimal thickening and fibrosis characteristic of advanced lesions (25) . In the prothrombotic state, intravascular thrombosis and fibrin deposition may be facilitated by either systemic or local deficits in fibrinolytic activity. Although systemic impairment of plasma fibrinolytic activity has been noted in patients with symptomatic coronary occlusive disease (reviewed in ref. 13) , the majority of patients with generalized arterial atherosclerosis exhibit normal plasma fibrinolytic profiles (26) . However, since localized alterations in fibrinolytic activity could also influence this process, we evaluated PAI-1 gene expression within segments of atherosclerotic human arteries.
Northern blot analysis of total RNA isolated from arterial segments (Fig. 1) 2 and 2.3 kb) , which contain identical codogenic regions but differ in the length of their 3' untranslated regions (21) , were increased in 11 severely atherosclerotic vessels compared with 5 normal-appearing or mildly involved vessels. The increase of PAT-i mRNA appeared to be a function of atherosclerotic and not aneurysmal involvement, since 2 specimens from undilated atherosclerotic vessels demonstrated the same characteristic pattern of PAI-1 mRNA expression. Quantitative analysis of data obtained from the 16 arterial specimens (Fig. 2) indicated that the mean PAT-i mRNA level was significantly increased in severely atherosclerotic arteries (mean densitometric value, 1.7 + 0.28 SEM) relative to normal-appearing vessels (mean densitometric value, 0.63 ± 0.09 SEM; P < 0.05).
In situ hybridization analysis of the severely diseased vessels (Fig. 3B ) revealed an intense hybridization signal for PAT-i mRNA in cells clustered about the base and sides ofthe plaque. The appearance and distribution of these cells resembles that of the mesenchymal-appearing intimal cells (MICs), assumed to be modified smooth muscle cells (27) , which predominate in advanced atherosclerotic lesions. The nature of the stimulus for the increased expression of PAT-i mRNA by these cells is unclear. Platelet-derived growth factor (PDGF) is the main chemotactic and mitogenic factor for smooth muscle cells and appears to be significantly involved in atherogenesis (28) . Previous in situ hybridization studies have demonstrated mRNA for both the PDGF-A and -B chains and the PDGF-b receptor (29) in MICs within atherosclerotic plaques. In human coronary atheromas, tissue factor (TF) mRNA and protein were visualized in macrophages and monocytes adjacent to the cholesterol clefts and within cells resembling MICs (30) . In preliminary experiments, PAT-i mRNA was colocalized to cells expressing PDGF and PDGF receptor (31) . In vitro, PDGF was shown to induce TF mRNA in murine 3T3 cells (32) and to stimulate PAT-i gene expression and biosynthesis in cultured bovine vascular smooth muscle cells (33) . Collectively, these observations suggest that PDGF may act in an autocrine or paracrine fashion to increase PAT-i and TF expression in atheromatous vessels.
In situ hybridization of normal-appearing or mildly involved aortic segments (Fig. 3A Upper) revealed a distinct positive hybridization signal for PAT-i mRNA in luminal aortic endothelial cells, while no hybridization signal could be detected in the endothelium of adventitial vessels within these segments (Fig. 3A Lower Right) . A similar pattern of PAT-i gene expression was observed in normal-appearing tissues obtained from the same patients as the severely atherosclerotic vessels (data not shown). The presence of PAT-i mRNA in luminal aortic endothelial cells and its absence in endothelial cells of adventitial vessels may simply reflect phenotypic differences between large and small vessel endothelium. However, other observations raise the possibility that endothelial PAT-i mRNA expression in vivo may be characteristic of an activated endothelium. For example, in human colon adenocarcinomas, PAT-i mRNA was shown to be present in endothelial cells of vessels immediately surrounding invasive tumor glands, while no hybridization signal could be visualized in biopsies of normal human colon (34) . Similarly, in murine renal tissues, a strong hybridization signal for PAT-i mRNA was evident in endothelial cells after treatment of mice with lipopolysaccharide, while no signal could be detected in the endothelium of normal mice (35) . In vitro the expression of PAT-i mRNA in cultured aortic endothelial cells is dramatically increased in response to inflammatory mediators, including interleukin 1 and tumor necrosis factor a (20, 36) as well as transforming growth factor p (20) , which is released from activated platelets during thrombosis (37) . The expression of PAIT-mRNA in luminal endothelial cells of normal-appearing aortic tissue (Fig. 3A) may thus reflect localized activation of the endothelium by humoral mediators released as a consequence of inflammatory or thrombotic processes in the vicinity of the sampling site. Alternatively, this phenomenon may reflect incipient atherogenesis within the vessel wall itself, since activation of the endothelium may precede the appearance of histologically defined lesions (38) . The histologically "normal" tissues used in this study may therefore not be truly representative of normal endothelium, and the data presented in Fig.  3A should be interpreted with this caution.
Newly synthesized PAI-1 is deposited into the extracellular matrix of vascular endothelial and smooth muscle cells in culture (39, 40) and appears to preserve extracellular matrix structures from degradation initiated by cellular proteases released during cell migration and tissue remodeling. By limiting extracellular proteolysis in developing atherosclerotic lesions, PAI-1 may thus play a significant role not only in the organization and incorporation of mural thrombi within the plaque but also in the neointimal proliferation of smooth muscle cells and in neovascularization of the plaque. In addition to PDGF, numerous other factors have been implicated in these processes, including basic fibroblast growth factor, which is angiogenic in vivo (41) and induces PAI-1 biosynthesis in capillary endothelial cells in vitro (42) . The presence of basic fibroblast growth factor within the plaque may elicit the endothelial expression of PAI-1 mRNA observed in arterioles and vasa vasorum of the diseased vascular segments (Fig. 3B) . Alternatively, the recent demonstration of tumor necrosis factor a immunoreactivity in endothelial, smooth muscle, and monocytic cells within atherosclerotic tissues (43) suggests this cytokine may also contribute to the observed pattern of PAI-1 mRNA expression in the diseased vessels (Fig. 3) .
The effect of increased PAI-1 gene expression in severely atherosclerotic vessels on its concentration in plasma is presently unclear. Plasma PAI-1 activity does not appear to correlate with the severity of coronary atherosclerosis in otherwise healthy men (18) . Moreover, the majority of patients with generalized arterial atherosclerosis exhibit normal plasma fibrinolytic profiles (26) . However, since increased plasma PAI-1 levels have been observed in individuals with metabolic disorders predisposing the development of atherosclerosis (e.g., hypertriglyceridemia; for review, see ref. 13) , the existence of a relationship between increased vascular PAI-1 expression and the incidence of systemic hypofibrinolysis in these individuals cannot presently be excluded.
Locally, the coincident expression of PAI-1 and TF within the plaque may both instigate and prolong thrombotic events within the vessel wall. A large body of evidence from histopathologic examination of human atheromas has demonstrated that such events are likely to occur repeatedly in growing atherosclerotic lesions. The subsequent organization and incorporation of mural thrombi within these lesions has been postulated to promote the neointimal proliferation and sclerosis characteristic of advanced disease. In addition, the presence of PAI-1 and TF in the body of the plaque may contribute to occlusive and potentially fatal thrombotic events following plaque rupture. Elucidation of the agents and mechanisms governing expression of these prothrombotic molecules may provide additional therapeutic venues for the control of atherosclerotic and cardiovascular disease.
